07:00 , Oct 8, 2007 |  BC Week In Review  |  Company News

WaferGen management update

WaferGen Biosystems Inc. (WGBS), Fremont, Calif.   Business: Supply/Service   Hired: Sharat Singh as SVP of R&D, formerly CSO of Aclara BioSciences Inc.; and Christopher Maki as VP of worldwide sales, formerly director of sales of...
07:00 , Jun 19, 2006 |  BC Week In Review  |  Company News

Monogram deal

MGRM said it will pay $57 million in cash to satisfy outstanding contingent value rights (CVRs). The CVRs were issued to Aclara shareholders in December 2004, when that company merged with MGRM (then Virologic). The...
01:18 , Jun 13, 2006 |  BC Extra  |  Company News

Monogram to pay Aclara shareholders $57M

Diagnostic company MGRM said it will pay $57 million in cash to satisfy outstanding contingent value rights (CVRs). The CVRs were issued to Aclara shareholders in December 2004, when that company merged with MGRM (then...
08:00 , Dec 20, 2004 |  BC Week In Review  |  Company News

Aclara, ViroLogic deal

The companies completed their previously announced merger to create a personalized medicine company focused on cancer and infectious diseases. Each outstanding share of ACLA was exchanged for 1.7 VLGC shares and 1.7 Contingent Value Rights...
08:00 , Dec 6, 2004 |  BC Week In Review  |  Company News

Aclara, Iceland Genomics Corp. deal

ACLA will use its eTag assays to validate cancer biomarkers from tumor samples provided by IGC. Iceland Genomics also will provide ACLA with blood samples and corresponding blinded patient data. ACLA will provide funding to...
08:00 , Nov 8, 2004 |  BC Week In Review  |  Clinical News

eTag: Pilot trial data

In a Japanese pilot study in 13 patients with breast cancer, eTag correctly differentiated responders from non-responders to Herceptin treatment. Herceptin is marketed by Genentech Inc. (DNA, South San Francisco, Calif.). Data were...
07:00 , Oct 11, 2004 |  BC Week In Review  |  Company News

Aclara, GlaxoSmithKline deal

GSK will evaluate ACLA's eTag assays for use in selecting patients to receive certain GSK cancer therapeutics based on biomarker assessment. GSK will provide drug-treated samples and will fund the study. Aclara BioSciences Inc. (ACLA),...
07:00 , Jul 12, 2004 |  BC Week In Review  |  Company News

Aclara scientific advisory board update

Aclara BioSciences Inc. (ACLA), Mountain View, Calif.   Business: Diagnostic, Cancer   Appointed: Roy Herbst, associate professor at the University of Texas M.D. Anderson Cancer Center   ...
07:00 , Jun 21, 2004 |  BC Week In Review  |  Company News

Aclara, Tokyo Metropolitan Institute of Medical Science deal

The parties will study breast cancer patient samples in an effort to validate cancer biomarkers detected with ACLA's eTag technology. The deal combines the institute's tumor samples and patient data with ACLA's eTag, and will...
07:00 , Jun 14, 2004 |  BC Week In Review  |  Company News

Aclara scientific advisory board update

Aclara BioSciences Inc. (ACLA), Mountain View, Calif.   Business: Diagnostic, Cancer   Appointed: Jose Baselga, professor of medicine at the Universidad Autonoma de Barcelona   ...